Prof. Gill Bejerano – Stanford University

Biography

Gill Bejerano is a Professor at Stanford University. He holds a B.Sc. In Mathematics, Physics and Computer Science, and a Ph.D in Computer Science (Machine Learning applications in Biology) from Hebrew University of Jerusalem. Gill got into genomics in 2003, started a wet lab in 2007, began analyzing patient genomes and medical records in 2014, got into cryptogenomics in 2017 and has become very interested in healthcare economics and patient risk management in 2021. He is recognized by multiple academic awards including two best paper and tomorrow’s PI awards, Mallinckrodt, Sloan, Human Frontiers, Searle, Okawa, David and Lucile Packard, Microsoft and Sony Scholar awards. Gill has trained, collaborated and advised computational scientists, experimentalists, clinicians, and MBAs and has helped both start-ups and Fortune 500 companies.


Prof. Alireza Haghighi – Harvard Medical School

Biography

Dr. Haghighi is the Director of International Center for Genetic Disease at Brigham and Woemen’s Hospital, Harvard Medical School. He is an American Board certified geneticist and clinician scientist, an Assistant Professor of Medicine at the Department of Medicine, Harvard Medical School. Dr. Haghighi has served as the Lead Clinical Molecular Geneticist at Harvard Brigham Genomic Medicine, an integrated clinical and research program that uses genomics and biological validation to (1) discover genetic causes of undiagnosed monogenic diseases, and (2) to devise improved or novel diagnostics or treatments. He completed his studies at University of Oxford, and Harvard Medical School, and was based at the Wellcome Trust Centre for Human Genetics before moving to Harvard. His research focuses on clinical and genetic investigation of inherited diseases and discovering novel disease genes, using a combination of genomic technologies such as whole genome sequencing, and RNAseq. He also works on translating the research discoveries into better diagnostics and improved management strategies, and opportunities for developing novel therapeutics to treat diseases. Dr. Haghighi is the President of Advancement Initiative for Medicine and Science (AIMS), a global foundation dedicated to the advancement of medicine and science around the world. AIMS brings together world-class academics and physicians (from the US and Europe), and work with governments and universities in partner countries in order to develop and implement different knowledge and expertise transfer programs with the aim of building capacity in medicine and surgery there. Dr. Haghighi has led many national and international projects for advancing medical science in different countries to improve the health and well-being of people. He provides consultation to governments, and academic and industrial organizations and institutes.


Prof. Mien-Chie Hung -China Medical University

Biography

Mien-Chie Hung, Ph.D. is the President for China Medical University in Taichung, Taiwan. He was vice president for basic research and professor and chair of the Department of Molecular and Cellular Oncology at The University of Texas MD Anderson Cancer Center. Dr. Hung is a basic scientist with a keen translational vision and especially his recent research effort has significantly contributed to understanding the biology of cancer and to developing combinational cancer therapies to overcome resistance. Up to date, Dr. Hung has published about 600 peer-reviewed articles, of which over 150 were published in journals with impact factor 10 or above. His lifetime h-index reaches to 154 (Google Scholar). He is one of members of Selection Committee for Tang Prize in Biopharmaceutical Science category and founding Editorial Members for Cancer Cell. He also serves as Editor-in-chief for American Journal for Cancer Research (2015-2017, 2019 till present) and Senior Editor for Cancer Research (American Association for Cancer Research, 2018-2021). Dr. Hung was inducted as an Academician of the Academia Sinica in Taiwan in 2002 and as a Fellow in Biological Sciences section, American Association for the Advancement of Science in 2010. His laboratory has a long term commitment to the following research areas: 1) Unravel non-canonical signal pathways of Epidermal Growth Factor Receptor (EGFR); 2) Identification of crosstalk signaling pathways in cancer cells to predict resistance for targeted therapy; 3) Elucidation of posttranslational modifications that play critical roles in tumor progression; 4) Discovery of signaling pathways and key regulators that are specific and critical to cancer stem cells proliferation; 5) Development of effectively immunotherapy and study of resistant mechanisms of immunotherapy; 6) screening natural products for anti-SARS-CoV-2.


Prof. Antonios Mikos – Rice University

Biography

Antonios G. Mikos is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering at Rice University. He is the Director of the National Institutes of Health Center for Engineering Complex Tissues, the Director of the Center for Excellence in Tissue Engineering, and the Director of the J.W. Cox Laboratory for Biomedical Engineering at Rice University. He received his Dipl.Eng. (1983) from the Aristotle University of Thessaloniki, Greece, and his Ph.D. (1988) in chemical engineering from Purdue University. He was a postdoctoral researcher at the Massachusetts Institute of Technology and the Harvard Medical School before joining the Rice Faculty in 1992 as an assistant professor. Mikos’ research focuses on the synthesis, processing, and evaluation of new biomaterials for use as scaffolds for tissue engineering, as carriers for controlled drug delivery, as non-viral vectors for gene therapy, and as platforms for disease modeling. His work has led to the development of novel orthopaedic, dental, cardiovascular, neurologic, and ophthalmologic biomaterials. He is the author of over 640 publications and 32 patents. He is the editor of 15 books and the author of one textbook (Biomaterials: The Intersection of Biology and Materials Science, Pearson Prentice Hall, 2008). Mikos is among the top 1 percent most cited researchers in his field. He has been cited over 83,000 times and has an h-index of 150. Mikos is a Member of the National Academy of Engineering, a Member of the National Academy of Medicine, a Member of the International Academy of Medical and Biological Engineering, a Member of the Academia Europaea, a Member of the Academy of Medicine, Engineering and Science of Texas, and a Member of the Academy of Athens. 


Prof. Soumya Raychaudhuri -Harvard Medical School

Biography

Soumya Raychaudhuri serves as the Director for the Center for Data Sciences (BWH, HMS) and is appointed as an Associate Member at the Broad Institute. Additionally he is clinically active and sees patients at Brigham and Women’s Hospital Arthritis Center. After completing his MD/PhD at Stanford University, Raychaudhuri pursued clinical training in internal medicine, and then went on to pursue subspecialty training in rheumatology at Brigham and Women’s Hospital. He concurrently completed postdoctoral training in human genetics at the Broad Institute with Dr. Mark Daly. Since joining the faculty at Harvard Medical School in 2010, he has contributed to the understanding of the genetic basis of rheumatoid arthritis and other immune-mediated diseases. He has also been at the forefront of devising statistical and computational methods to localize genetic association signals to causal variants, and to interpret human genetic data in the context of functional information. He currently has active research programs in the human genetics and functional genomics of tuberculosis, type I diabetes, and rheumatoid arthritis, with a specific focus on using genomic strategies to understand CD4+ T cell biology.